Alcaraz at 12¢: Why the Market Is Pricing Him Out of His Own Defense

TL;DR

Alcaraz is priced at 12¢ (YES) to win the 2026 Men's US Open, nine days before the tournament begins on August 24.
He has not played competitive tennis since late April, missing the Italian Open, French Open, Wimbledon, and Cincinnati — all due to right wrist tenosynovitis.
Andy Roddick said publicly on August 12 that the US Open is "in doubt" for Alcaraz, and that a best-of-five return from a five-month layoff would contradict everything he has done to protect the injury.
At 12¢, the market is not being pessimistic — it is doing its job.

The defending champion of the 2026 Men's US Open is priced at 12¢ to win it again. That is not a market inefficiency. That is a market doing honest arithmetic on a complicated medical situation.

What the Market Says

At 2026-08-15 10:23 UTC, Polymarket's contract on whether Carlos Alcaraz wins the 2026 Men's US Open sits at YES 12¢ and NO 88¢, with a resolution date of 2026-09-13. The 24-hour volume at capture was $1,186 — thin, but not irrelevant.

Worth noting: this market was sitting at 10¢ as recently as August 6, before the Cincinnati withdrawal was formally confirmed. It has since moved to 12¢. That is a small upward tick against a backdrop of worsening news, which tells you something. Either the market had already priced in the worst-case scenario before the confirmation landed, or a sliver of smart money decided that a 10¢ floor was too harsh for a 21-year-old former world number one who could theoretically show up healthy and tear through a draw. Both explanations are defensible. Neither is bullish.

For context: a healthy Alcaraz at peak form would likely trade somewhere between 20¢ and 30¢ in this field, given competition from Jannik Sinner — who is co-favored at 52¢ — and a full slate of players who have had an uninterrupted summer of match play. The gap between 25¢ and 12¢ is entirely explained by the injury and the five-month absence. The market is not discounting Alcaraz the tennis player. It is discounting Alcaraz the question mark.

The Case

The facts are straightforward and not in dispute. Alcaraz won the Australian Open in February and the Qatar Open in the spring. He then withdrew from the Barcelona Open in late April after his opening-round match, following a diagnosis of right wrist tenosynovitis confirmed by medical testing. He has not played a competitive match since. The list of tournaments he has missed is a reasonable facsimile of the entire clay and grass calendar: Italian Open, French Open, Queen's Club, Wimbledon. He withdrew from the Cincinnati Open on August 10-12, just two weeks before the US Open draw.

That last point is the one the market is really chewing on. Cincinnati withdrawal means Alcaraz arrived at the final hard-court tune-up event for the US Open and decided — or was advised — not to play. The US Open is a best-of-five-sets event. Cincinnati is best-of-three. If he could not commit to Cincinnati, the logical inference about a longer, more physically demanding tournament is not encouraging.

Andy Roddick, former world number one, made exactly this argument on his Served with Andy Roddick podcast on August 12. As reported by Yahoo Sports, Roddick said:

"I think it's really hard to come back and have your first tournament be three out of five sets. I think the U.S. Open's in doubt...That would be counter to everything that he has done this far with taking his time and being patient with his injury."

Roddick is not a pessimist by default, and his framing here is notable for its precision. He is not saying Alcaraz is done. He is saying that what Alcaraz has done — every decision since April — reflects a deliberate, conservative approach to protecting the wrist. Walking into a Grand Slam as your re-entry point, after five months off, would contradict that pattern entirely. If the pattern holds, the US Open is a scratch. If it breaks, you have to ask why.

The 88¢ NO contract is pricing in two compounding probabilities: first, that Alcaraz does not enter the tournament at all; second, that even if he does enter, his chances of winning seven best-of-five matches from a standing start — against a field that includes a 52¢ favorite in Sinner and multiple other contenders with full match fitness — are considerably below his historical baseline. Both legs of that argument are reasonable.

The defending champion is, effectively, an absentee title holder. The market has priced that correctly.

Risks

The honest case for YES at 12¢ begins with age and talent. Alcaraz is 21 years old. Wrist tenosynovitis, while serious, is not a structural career-ending injury in the way a torn ligament can be. Young athletes with access to elite sports medicine programs recover faster and more completely than the general population. Five months is a long time off, but it is also five months of rest, treatment, and — crucially — possible sport-specific conditioning work that has not been reported publicly. Absence of news is not evidence of stagnation.

There is also the question of what "not competitive" actually means. Alcaraz has not played matches. He may have been hitting on a practice court for weeks. The match-rust argument is real, but it can be overstated if the physical mechanics are intact and the player is sharp in training. Grand Slam champions have historically been capable of surprising the field when returning from injury, provided the injury is genuinely resolved.

And then there is the simple math of 12¢. If you genuinely believe there is a 15% or 20% chance that Alcaraz shows up healthy, finds his form through the draw, and lifts the trophy — and a healthy Alcaraz is absolutely capable of that — then 12¢ is underpriced. The question is whether you believe the wrist is resolved. The Cincinnati withdrawal suggests it is not, or at least not enough to risk it. But "not enough to risk Cincinnati" and "not enough to win the US Open" are not the same sentence, even if they rhyme.

The tail risk for NO holders is a healthy, motivated Alcaraz who decided Cincinnati was unnecessary preparation and saved himself for the main event. It is not the most likely scenario. But at 12¢, the market is not ruling it out — it is simply saying it is unlikely. That is an accurate statement, not a prediction.

Sources: Yahoo Sports / Tennis World USA, Aug 11–12, 2026; Andy Roddick, "Served with Andy Roddick" podcast, aired Aug 12, 2026, as quoted by Yahoo Sports; Polymarket, captured 2026-08-15 10:23 UTC.

Prices captured at press time and are not live. Not financial advice.